NASDAQ:RELVReliv International Stock Price, Forecast & News

Reliv International's stock was trading at $3.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RELV shares have increased by 26.5% and is now trading at $4.11.
View which stocks have been most impacted by Coronavirus.

Reliv International is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Reliv International.

Reliv International, Inc (NASDAQ:RELV) posted its quarterly earnings results on Friday, May, 15th. The company reported $0.38 earnings per share (EPS) for the quarter. The business earned $10.28 million during the quarter. Reliv International had a negative net margin of 1.13% and a negative return on equity of 3.52%.
View Reliv International's earnings history.

Media headlines about RELV stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Reliv International earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Reliv International.

Reliv International saw a decrease in short interest in July. As of July 15th, there was short interest totaling 1,200 shares, a decrease of 42.9% from the June 30th total of 2,100 shares. Based on an average trading volume of 15,900 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company's stock are sold short.
View Reliv International's Short Interest.

Some companies that are related to Reliv International include KemPharm (KMPH), AzurRx BioPharma (AZRX), Spring Bank Pharmaceuticals (SBPH), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Akorn (AKRXQ), Adial Pharmaceuticals (ADIL), Cyclacel Pharmaceuticals (CYCC), IntelGenx Technologies (IGXT), Pharmaxis (PXSLY), OHR Pharmaceutical (OHRP), ProPhase Labs (PRPH), AEterna Zentaris (AEZS), Iterum Therapeutics (ITRM), MYOS (MYOS) and Uluru (ULUR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Reliv International investors own include NovaBay Pharmaceuticals (NBY), Gold Standard Ventures (GSV), Gold Standard Ventures (GSV), Primo Water (PRMW), Rite Aid (RAD), RadNet (RDNT), Ring Energy (REI), Ring Energy (REI), VIVUS (VVUS) and Acer Therapeutics (ACER).

Reliv International trades on the NASDAQ under the ticker symbol "RELV."

Shares of RELV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RELV stock can currently be purchased for approximately $4.11.

Reliv International has a market capitalization of $7.19 million and generates $35.06 million in revenue each year. Reliv International employs 156 workers across the globe.

The official website for Reliv International is www.reliv.com.

Reliv International's mailing address is 136 CHESTERFIELD INDUSTRIAL BLVD, CHESTERFIELD MO, 63006. The company can be reached via phone at 636-537-9715 or via email at [email protected]